How Has The Generic Injectables Market Size Evolved In Recent Years?
The generic injectables market has seen considerable growth due to a variety of factors.
•The size of the generic injectables market has experienced rapid expansion in the recent past. Anticipated growth is from $124.61 billion in 2024 to $143.13 billion in 2025, marking a compound annual growth rate (CAGR) of 14.9%.
Factors such as cost-effectiveness, expiration of patents, initiatives for healthcare accessibility, market rivalry, as well as worldwide pharmaceutical trends have contributed to its growth in the historical period.
What Is The Projected Growth Of The Generic Injectables Market?
The generic injectables market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations indicate a rapid expansion in the generic injectables market size in the coming years, with projections set at "$238.43 billion by 2029, reflecting a compound annual growth of 13.6%.
Factors contributing to this predicted growth during the forecast period include growing elderly population, strategic partnerships, changes in regulatory environment, heightened healthcare consciousness, and innovative developments in the market. Key trends anticipated during this period include prioritizing quality and regulatory adherence, implementation of the 505 (b) (2) regulatory protocol, progression in unique drug delivery technologies, industrial collaborations and partnerships, and an amplified emphasis on specialty injectable treatments.
What Are The Key Drivers Fueling Growth In The Generic Injectables Market?
The growing occurrences of cancer and cardiovascular diseases are set to drive the expansion of the generic injectable market. Cardiovascular diseases constitute a collection of disorders affecting the heart and blood vessels, while cancer is a condition characterised by uncontrolled and spreading growth of the body's cells. Generic injectables, which offer pharmaceutical equivalence or bioequivalence to branded drugs, are utilized for cancer and cardiac disease treatment, facilitating greater drug availability and accessibility for more cost-effective treatment. As an illustration, in September 2022, the World Health Organization, a UN-specialized agency based in Switzerland, reported 41 million deaths. This counts for 74% of deaths from noncommunicable diseases (NCDs) or chronic diseases every year globally. Among these, 17.9 million deaths resulted from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Consequently, the increasing occurrences of cancer and cardiovascular diseases are fuelling the expansion of the generic injectable market.
What Are The Principal Market Segments In The Global Generic Injectables Industry?
The generic injectables market covered in this report is segmented –
1) By Product Type: Monoclonal Antibodies, Cytokines, Insulin, Vaccines, Other Products
2) By Container Type: Vials, Ampoules, Premix, Prefilled Syringes, Other Containers
3) By Route Of Administration: Intravenous, Intramuscular, Subcutaneous, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Drug Stores, Online Prescription Stores
5) By Application: Oncology, Diabetes , Infectious Diseases , Blood Disorders , Musculoskeletal Disorders , Hormonal Disorders , Pain Management , CNS Diseases , Cardiovascular Diseases
Subsegments:
1) By Monoclonal Antibodies: IgG Monoclonal Antibodies, IgM Monoclonal Antibodies, Other Types Of Monoclonal Antibodies
2) By Cytokines: Interferons, Interleukins, Tumor Necrosis Factor (TNF) Inhibitors
3) By Insulin: Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin
4) By Vaccines: Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines
5) By Other Products: Hormones, Peptides, Enzymes
Pre-Book The Generic Injectables Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Generic Injectables Sector?
Product innovation is increasingly becoming a significant trend in the generic injectables market. Leading companies in this market are continuously refining their generic injectable products to maintain their market standing. Take for example, Dr. Reddy’s Laboratories, a pharmaceutical company from India, who in April 2022, introduced their Treprostinil Injection in the U.S. market. This medication is a generic equivalent of the approved Remodulin (treprostinil) Injection by the U.S. Food and Drug Administration (USFDA), a US-based entity. The drug serves patients who need to switch from epoprostenol to reduce the likelihood of clinical decay.
Who Are the Key Players in the Generic Injectables Market?
Major companies operating in the generic injectables market include:
• Baxter International Inc.
• Sanofi SA
• AstraZeneca plc.
• Fresenius Medical Care AG & Co. KGaA
• Johnson & Johnson
• Merck & Co. Inc.
• Biocon Limited
• Lupin Limited
• Dr. Reddy's Laboratories Ltd.
• Teva Pharmaceutical Industries Ltd.
• Cipla Limited
• Aurobindo Pharma Limited
• Samsung Biologics Co. Ltd.
• Piramal Pharma Limited
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Hikma Pharmaceuticals PLC
• Par Pharmaceutical
• Pharmascience Inc.
• SAGENT Pharmaceuticals
• AmerisourceBergen Corporation
• Hospira Inc.
• Sandoz International GmbH
• Singota Solutions Inc.
• MVASI Bevacizumab-awwb Syringes
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd.
• Endo International plc
• Akorn Pharmaceuticals Inc.
• Wockhardt Limited
What are the Regional Insights into the Generic Injectables Market?
North America was the largest region in the generic injectable market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generic injectables market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
